This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 1999;282:19.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has issued a public health advisory to inform physicians and the public regarding new safety information about trovafloxacin/alatrofloxacin (Trovan, Trovan-IV), a quinolone antibiotic marketed since February 1998 for a broad range of infections. Based on new safety data related to serious liver injury, the manufacturer has agreed to limit distribution of the product to hospitals and long-term nursing care facilities, and the FDA is advising physicians that the drug should be reserved for treatment only in patients who meet all of the following criteria:

• The patient has at least one of the following types of infections that are judged by the treating physician to be serious and life- or limb-threatening: nosocomial pneumonia; community-acquired pneumonia; complicated intra-abdominal infections, including postsurgical infections; gynecological and pelvic infections; and complicated skin and skin structure infections, including diabetic foot infections.
  
• The patient begins his or her therapy in inpatient health care facilities (ie, . . . [Full Text of this Article]